Back to LGND Stock Lookup

Ligand Pharma (LGND) –

Nov 25, 2016 05:58 PM Form 4 LIGAND PHARMACEUTICALS For: Nov 22 Filed by: Aryeh Jason
Nov 21, 2016 07:30 AM Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016
Nov 21, 2016 06:42 AM Roth Capital Affirms Ligand Pharma (LGND) at 'Buy' Following Presentation of New Phase 2 DUET Data (RTRX)
Nov 18, 2016 04:49 PM Form 4 LIGAND PHARMACEUTICALS For: Nov 16 Filed by: Aryeh Jason
Nov 15, 2016 06:07 AM Form 10-Q LIGAND PHARMACEUTICALS For: Sep 30
Nov 15, 2016 06:07 AM Form 10-Q/A LIGAND PHARMACEUTICALS For: Jun 30
Nov 15, 2016 06:07 AM Form 10-Q/A LIGAND PHARMACEUTICALS For: Mar 31
Nov 15, 2016 06:06 AM Form 10-K/A LIGAND PHARMACEUTICALS For: Dec 31
Nov 14, 2016 05:50 PM Form 8-K LIGAND PHARMACEUTICALS For: Nov 14
Nov 9, 2016 08:31 AM Form NT 10-Q LIGAND PHARMACEUTICALS For: Sep 30
Nov 3, 2016 04:51 PM Ligand Pharma (LGND) Tops Q3 EPS by 3c
Nov 3, 2016 04:05 PM Form 8-K LIGAND PHARMACEUTICALS For: Nov 03
Nov 3, 2016 04:01 PM Ligand Reports Third Quarter 2016 Financial Results
Nov 3, 2016 06:05 AM Form SC 13G/A LIGAND PHARMACEUTICALS Filed by: RS INVESTMENT MANAGEMENT CO LLC
Nov 2, 2016 02:08 PM Trading Radar for 11/3: GoPro (GPRO), Chesapeake (CHK), Activision (ATVI), Fossil (FOSL), Starbucks (SBUX) Report
Nov 1, 2016 08:19 PM Form 4 LIGAND PHARMACEUTICALS For: Oct 31 Filed by: Davis Todd C
Oct 24, 2016 09:28 AM Ligand Pharma (LGND) Announces Submission of Baxdela NDAs to FDA as ABSSSI Treatment
Oct 24, 2016 09:21 AM Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections
Oct 13, 2016 09:00 AM Ligand Announces Third Quarter 2016 Earnings Release Date and Participation in the Stephens Fall Investment Conference
Oct 10, 2016 06:24 AM Ligand Pharma (LGND) Partner Lundbeck Granted FDA Approval of Carnexiv
Oct 7, 2016 06:17 PM Ligand Partner Lundbeck Receives FDA Approval of Carnexiv™ (carbamazepine) Injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types
Oct 5, 2016 07:49 AM Ligand Pharma (LGNT) PT Raised to $160 at H.C. Wainwright
Sep 27, 2016 10:15 AM Roth Capital Trims PT on Ligand Pharma (LGND) to $150 Amid New Kyprolis Data (AMGN)
Sep 23, 2016 04:20 PM Form 4 LIGAND PHARMACEUTICALS For: Sep 22 Filed by: HIGGINS JOHN L
Sep 22, 2016 04:06 PM Form 8-K LIGAND PHARMACEUTICALS For: Sep 22
Sep 22, 2016 10:50 AM Form 8-K LIGAND PHARMACEUTICALS For: Sep 22
Sep 22, 2016 09:02 AM Ligand Pharma (LGND) Enters Licensing Agreements with Seelos Therapeutics for Four Programs
Sep 22, 2016 09:00 AM Ligand Licenses Four Programs to Seelos Therapeutics
Sep 16, 2016 09:28 AM Form CT ORDER LIGAND PHARMACEUTICALS
Sep 16, 2016 09:00 AM Ligand Enters OmniAb® License Agreement with TeneoBio, Inc.
Sep 13, 2016 12:29 PM Roth Capital Affirms Ligand Pharma (LGND) at 'Buy' Following Initiation of LGD-6972 Phase 2 in T2D
Sep 13, 2016 08:30 AM Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes
Sep 9, 2016 04:06 PM Form 4/A LIGAND PHARMACEUTICALS For: Sep 01 Filed by: KOZARICH JOHN W
Sep 9, 2016 04:06 PM Form 4 LIGAND PHARMACEUTICALS For: Sep 07 Filed by: KOZARICH JOHN W
Sep 7, 2016 12:04 PM Streetinsider.com's Hot Lunchtime Reads 9/7: (AMD) (LGND) (EXPR) (GILD)
Sep 7, 2016 11:00 AM Roth Capital Bumps PT on Ligand Pharma (LGND) up to $151 Following Sparsentan Data; Affirms at 'Buy'
Sep 7, 2016 10:14 AM Notable Analyst Rating Changes 9/7: (LGND) (GLPI) (DIN) Upgraded; (MNTA) (OLN) (TNXP) Downgraded
Sep 7, 2016 09:26 AM Ligand Pharma (LGND) Says Retrophin (RTRX) Presented Sparsentan Phase 2 Study Data
Sep 7, 2016 09:25 AM Ligand Partner Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis
Sep 7, 2016 07:40 AM Ligand Pharma (LGND) Gains After Retrophin (RTRX) Announces Positive Sparsentan Phase 2 Data
Sep 7, 2016 07:20 AM Deutsche Bank Upgrades Ligand Pharma (LGND) to Hold
Sep 7, 2016 06:53 AM Roth Capital Positive on Ligand Pharma (LGND) Ahead of Sept. Catalysts; Affirms at 'Buy'
Sep 6, 2016 06:07 PM Form 4 LIGAND PHARMACEUTICALS For: Sep 01 Filed by: KOZARICH JOHN W
Sep 2, 2016 09:00 AM Ligand to Participate in Two Upcoming Investor Conferences
Sep 1, 2016 06:00 AM Intec Pharma Reports First Half 2016 Financial Results
Aug 26, 2016 08:40 AM Ligand Pharma (LGND) Board Approves Ernst & Young as Independent Registered Accounting Firm
Aug 26, 2016 08:32 AM Form 8-K LIGAND PHARMACEUTICALS For: Aug 22
Aug 15, 2016 09:04 AM Ligand Pharma (LGND) Announces Publishing of Results from Phase 1 Trials with LGD-6972 in Type 2 Diabetes Mellitus
Aug 15, 2016 09:00 AM Results from Phase 1 Trials with Ligand’s LGD-6972 in Type 2 Diabetes Mellitus Published in Diabetes, Obesity and Metabolism
Aug 9, 2016 05:07 PM Form 4 LIGAND PHARMACEUTICALS For: Aug 05 Filed by: Berkman Charles S

Back to LGND Stock Lookup